Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

JAMA oncology

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
JAMA Oncology|November 13, 2015
Cognitive Changes During ChemotherapyVivek Subbiah
JAMA Oncology|March 5, 2026
Delivering Precision Oncology at Scale-Infrastructure, Evidence, and the Path ForwardVivek Subbiah
JAMA Oncology|April 15, 2016
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the DiagnosisVivek Subbiah, Razelle Kurzrock
JAMA Oncology|March 25, 2016
Bone Complications in Patients With CancerVivek Subbiah, Howard L West
JAMA Oncology|February 15, 2024
Modernize Precision Oncology With Decentralized Trial ToolsMuhammad Shaalan Beg, Vivek Subbiah
JAMA Oncology|July 15, 2016
Jaundice (Hyperbilirubinemia) in CancerVivek Subbiah, Howard Jack West
JAMA Oncology|July 17, 2015
Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier PenetrationVivek Subbiah, Pete Anderson, Eric Rohren
JAMA Oncology|May 26, 2018
Hypopigmented Skin Lesions After ImmunotherapyEcaterina Ileana Dumbrava, Doina Ivan, Vivek Subbiah
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
JAMA Oncology|November 13, 2015
Cognitive Changes During ChemotherapyVivek Subbiah
JAMA Oncology|March 5, 2026
Delivering Precision Oncology at Scale-Infrastructure, Evidence, and the Path ForwardVivek Subbiah
JAMA Oncology|April 15, 2016
Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the DiagnosisVivek Subbiah, Razelle Kurzrock
JAMA Oncology|March 25, 2016
Bone Complications in Patients With CancerVivek Subbiah, Howard L West
JAMA Oncology|February 15, 2024
Modernize Precision Oncology With Decentralized Trial ToolsMuhammad Shaalan Beg, Vivek Subbiah
JAMA Oncology|July 15, 2016
Jaundice (Hyperbilirubinemia) in CancerVivek Subbiah, Howard Jack West
JAMA Oncology|July 17, 2015
Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier PenetrationVivek Subbiah, Pete Anderson, Eric Rohren
JAMA Oncology|May 26, 2018
Hypopigmented Skin Lesions After ImmunotherapyEcaterina Ileana Dumbrava, Doina Ivan, Vivek Subbiah
JAMA Oncology|December 1, 2017
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET StudyEli L Diamond, Vivek Subbiah, A Craig Lockhart, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
Pageof 1